The Propel and Propel Mini are resorbable devices that deliver mometasone (a steroids) directly to the sinus lining. Several studies have confirmed the benefits of these devices, which seem to reduce the need for additional treatments. Originally designed for placement only at the time of surgery, these devices may also be placed into the surgically opened ethmoid cavity at any time point during regular office visits or during office procedures.
Propel is the first and only device clinically shown to keep the sinuses open after surgery, precisely deliver anti-inflammatory medication directly into the healing tissues, and then dissolve. The innovative sinus stent decreases post-operative scarring and inflammation, reducing the need for additional surgical procedures as well as oral steroids and their potential side effects. At the same time, PROPEL’s spring-like, lightweight design means patients usually cannot even tell that it is there.
Propel Contour is another version of this device. It is intended for placement directly at the sinus ostium. It is particularly helpful for achieving a good result at the frontal sinus.
Sinuva is a newer steroid implant. It is expressly designed for those patients with recurrent nasal polyps after sinus surgery. The implant delivers a higher dose of mometasone over a longer period of time (compared with Propel and Propel Mini), and Sinuva is intended for placement during routine office visits. Sinuva both opens the ethmoid sinus cavity and delivers steroids directly to the inflamed sinus tissue. Sinvua shrinks nasal polyps and reduces the symptoms of congestion and nasal blockage. After Sinuva treatment, many patients also report improvement in their sense of smell.